Company Filing History:
Years Active: 2008
Title: Belkis González Barrios: Innovator in Cancer Treatment
Belkis González Barrios is a notable inventor located in Playa, Cuba, recognized for her significant contributions to the field of molecular pharmacology. With a focus on developing innovative peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors, her work addresses critical challenges in oncology.
Latest Patents
Belkis holds a patent for her invention titled "Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors." This groundbreaking work reveals the identification of peptides that effectively block the Casein Kinase II (CKII) phosphorylation domain, facilitating direct interaction to combat HPV-associated oncogenic processes. The invention demonstrates eleven cyclic peptides with varying amino acid sequences, which inhibit CKII phosphorylation in vitro, exhibit cytotoxic benefits on HPV-16 transformed cells (CaSki), and enhance the effectiveness of interferon (IFN) treatments.
Career Highlights
Belkis González Barrios is affiliated with the Centro de Ingeniería Genética y Biotecnología, where her research notably contributes to the advancement of cancer therapies. Her innovative approach to identifying and utilizing specific peptides positions her at the forefront of molecular pharmacology, emphasizing precision and effectiveness in cancer treatment.
Collaborations
Throughout her career, Belkis has collaborated with esteemed colleagues such as Silvio Ernesto Perea Rodriguez and Osvaldo Reyes Acosta. These partnerships foster an environment of shared knowledge and expertise, driving forward the development of novel cancer therapies and expanding the possibilities for patient treatment.
Conclusion
Through her inventive work and dedication to addressing the complexities of cancer treatment, Belkis González Barrios exemplifies the spirit of innovation. Her patents and collaborations reflect a commitment to improving healthcare outcomes, particularly for patients dealing with HPV and associated epithelial tumors, solidifying her place as an influential figure in the field of molecular pharmacology.